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Efficacy of pamidronate in children with
chronic non-bacterial osteitis using whole
body MRI as a marker of disease activity
C. S. Bhat1 , M. Roderick1, E. S. Sen2,3, A. Finn1 and A. V. Ramanan1,2*
Abstract
Background: To study the response to pamidronate using whole body magnetic resonance imaging (WB-MRI) in
children with chronic non-bacterial osteitis (CNO) in a tertiary health centre.
Methods: The medical records of children under the age of sixteen with a diagnosis of chronic non-bacterial
osteitis between 2005 and 2018 were reviewed. All those who were treated with pamidronate were included and
relevant data was collected. Response to therapy was determined based on the status of lesions on WB- MRI.
Results: Forty six patients were included in the study. Pre- and post-treatment WB-MRI was available in forty
patients. Cumulative lesions pre-treatment were 150 and reduced to 45 (30%) post-treatment. Seventeen patients
(42.5%) had a good response with complete resolution of all lesions and nine patients (22.5%) worsened
during or following treatment with pamidronate. Vertebral disease had a good response and 82.3% of the
lesions resolved completely.
Conclusion: Our study describes the experience with pamidronate in a tertiary health centre using WB-MRI as
a marker of disease activity. Pamidronate was well tolerated in our cohort and treatment response was fairly good.
Significance and innovation: 1. Bisphosphonates can be used in the treatment of CNO when response to NSAIDs is
suboptimal. 2. In the presence of spinal or mandibular lesions bisphosphonates were used as first line. 3. Treatment
was escalated to a TNF blocker when response to bisphosphonates was suboptimal.
Keywords: Whole body MRI, Pamidronate, Spinal lesions
Background
Chronic non-bacterial osteitis (CNO) is an autoinflam-
matory disorder that predominantly affects metaphyses
of long bones. Bone pain and bone swelling are the usual
presenting symptoms [1]. Whole-body magnetic reson-
ance imaging (WB-MRI) is becoming increasingly
important for diagnosis and assessing treatment re-
sponse [2]. Non-steroidal anti-inflammatory drugs
(NSAIDs) are usually preferred first-line agents across
most centres. Second-line options include non-biologic
disease-modifying anti-rheumatic drugs (DMARDs),
bisphosphonates and anti-tumour necrosis factor (TNF)
agents. Initiating appropriate treatment with timely es-
calation is necessary to prevent complications especially
with vertebral or mandibular disease [3].
Apart from the Euro fever registry that included 486
patients [4], studies pub lished so far highlighting the ef-
fectiveness of bisphosphonates in CNO have included
only small numbers of patients [5, 6]. We report our ex-
perience of children with CNO treated with bisphospho-
nates over a 13-year period.
Methods
In this retrospective study, medical records of patients
diagnosed with CNO between 2005 and 2018 were
reviewed. Children with age of disease onset less than
16 years who received bisphosphonates were included in
the study. Demographics, clinical features, investigations
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and treatment received were recorded. WB-MRI was
used to identify sites of bone and soft tissue inflamma-
tion in active CNO.
MRIs were acquired from clinical 1.5 T scanners
(Siemens, Erlangen, Germany). All WB-MRIs included
in the study had coronal two-dimensional fast STIR T2
and T1 sequence images. Dedicated axial images were
obtained from specific sites depending on abnormalities
identified on the coronal images. If required, contrast-
enhanced MRIs were obtained after 0.1 mmol/kg of
intravenous gadolinium. According to the Bristol
diagnostic criteria [7], typical short tau inversion recov-
ery (STIR) MRI changes include bone marrow oedema
and/or bone expansion, lytic areas and periosteal reac-
tion. Scans were reported by one of the five paediatric
radiologists with musculoskeletal expertise at our centre.
Response to therapy based on the status of lesions on
WB-MRI was defined as:
 Good response - complete resolution of all lesions.
 Moderate response - combination of completely
resolved and significantly resolved or stable lesions.
 Mild response - partial improvement of existing
lesions or stable lesions.
 No response - combination of new lesions or
worsening of existing lesions and stable lesions.
In the absence of vertebral or mandibular disease
all patients had a trial of NSAIDs for at least a
month. Treatment was escalated if the desired clin-
ical response was not achieved and bisphosphonates
were the preferred second line agents. If the re-
sponse to bisphosphonates was suboptimal treatment
was switched to a TNF blocker. Bisphosphonates
were used as first line along with NSAIDs in those
with mandibular or vertebral disease.
Earlier, the practice was to use a short course of cortico-
steroids for 4 to 6 weeks or/and methotrexate for a period
of 18 to 24months prior to bisphosphonates but this is no
longer followed. In the subset that received corticosteroids
or/and methotrexate whole body MRI was repeated before
escalating treatment.
In our centre pamidronate was the preferred bis-
phosphonate. The dose of pamidronate varied de-
pending upon clinical response but was usually given
as 3-monthly cycles for a period of 12 months. Each
cycle consisted of 3 days of pamidronate at a dose of
1 mg/kg/day and a maximum of 60 mg/day. The max-
imum cumulative dose was 12 mg/kg/year. Additional
doses were given for persistent disease at the end of
12 months. Clinical response to treatment was
assessed after the first two cycles. Patients who re-
ported no improvement or had worsening of symp-
toms underwent a WB-MRI to assess disease activity.
Scans were otherwise obtained at diagnosis and prior
to escalation of treatment. In the subset that received
pamidronate WBMRI was usually repeated after com-
pletion of four cycles.
Results
Forty-six patients were included in the study and mean
follow up duration was 6 years (range 1–13 years).
Baseline characteristics are summarised in Table 1.
Pre-treatment WB-MRI was performed in all patients
and post-treatment WB-MRI was obtained in 40/46. Cu-
mulative lesions pre-treatment were 162. Prior to being
treated with pamidronate, thirty five patients had a trial
of NSAIDs, four patients (8.7%) received corticosteroids
and five (10.9%) had a trial of methotrexate. Treatment
was escalated to pamidronate due to poor clinical or
radiological response. NSAIDs along with bisphospho-
nates were used as first line in nine patients (19.5%) with
spinal lesions and two patients (4.3%) with mandibular
disease. Two patients discontinued treatment due to in-
fusion related side effects and four patients are receiving
ongoing treatment. Treatment response was assessed in
those with a post-treatment WB-MRI (n = 40, lesions =
150). Data collection has been summarised in Fig. 1.
Table 1 Baseline characteristics of patients
Female: Male 3.18: 1
Median age at diagnosis (IQR, years) 11.6 (10–13)
Median time to diagnosis (IQR,
months)
12 (5–24)
Clinical characteristics (%) Bone pain 36
(78.3)
Bone swelling 10
(21.7)
Synovitis 3 (6.5)
Arthritis 6 (13)
Pustulosis 3 (6.5)
Psoriasis 3 (6.5)
IBDa 1 (2.2)
Family history of psoriasis (%) 7 (15.2)
Family history of IBD (%) 2 (4.3)
Bone biopsy (%) 29 (63)
Lesions pre-treatment on WB-MRI 162
Treatment (%) NSAIDs 35 (76)
Pamidronate 46 (100)
Corticosteroids 4 (8.7)
Methotrexate 5 (10.9)
TNF blockers (n =
40)
5 (12.5)
aIBD Inflammatory bowel disease
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Twenty-seven patients (67.5%) completed 4 cycles of
pamidronate. Four patients (10%) required extra doses of
pamidronate because of persistent symptomatic disease.
Nine patients (22.5%) discontinued treatment after two cy-
cles due to poor clinical response. Treatment responses are
summarised in Tables 2 and 3. Five patients (12.5%) with
radiological evidence of persistent disease or worsening of
disease were commenced on a TNF blocker.
Nine patients had vertebral disease at presentation and
8/9 have completed treatment. Seventeen lesions were
detected prior to treatment with pamidronate of which
14 (82.3%) resolved completely (Fig. 2) but 3 (17.6%)
lesions persisted. One patient with collapsed vertebrae
received additional doses of pamidronate. Despite this,
follow-up imaging showed persistent disease and the
child was eventually commenced on adalimumab. An-
other patient with reduced vertebral height had stable
disease after four cycles of pamidronate. One patient de-
veloped sacroiliitis on follow up and was commenced on
adalimumab. Distribution of lesions has been sum-
marised in Table 4. Two patients had mandibular disease
at presentation and were commenced on pamidronate.
One patient discontinued treatment and post-pamidro-
nate WB-MRI is pending in the other patient.
Discussion
In our cohort, the number of radiologically apparent
lesions began at 150 and fell to 45 (30%) after treat-
ment with pamidronate. 82.3% of vertebral lesions re-
solved completely. This is in keeping with other
published studies demonstrating efficacy of pamidro-
nate [5, 6, 8–10].
Bisphosphonates have preferential affinity for sites of
active bone remodelling such as bone inflammation as is
seen in CNO. They limit both osteoblast and osteocyte
Fig. 1 Flowchart summarising patient selection and treatment options used prior to pamidronate
Table 2 Treatment response to pamidronate
Response Number of
patients (%)
(n = 40)
Lesions pre-
pamidronate
Lesions post-
pamidronate
Number
resolved
(%)
Good
response
17 (42.5) 37 0 37 (100)
Moderate
response
10 (25) 47 12 35 (74.5)
Mild
response
4 (10) 18 6 12 (66.7)
No
response
9 (22.5) 48 27 21 (43.7)
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apoptosis, reduce bone resorption and increase second-
ary mineralisation of bone. Suppression of bone resorp-
tion is maximum within 3 months of initiation of
therapy and is more rapid with intravenous than oral
therapy [11]. Pamidronate is hence the preferred bis-
phosphonate in our centre. The effects of pamidronate
can be hampered in those with vitamin D deficiency [11,
12]. In our cohort, Vitamin D levels were routinely
checked and corrected prior to treatment.
In the group that discontinued treatment due to poor
clinical response, 50% of the lesions had improved on
follow up WB-MRI. This highlights the importance of
using WB-MRI in assessing disease activity and response
to treatment. Persistent pain in children with
radiological remission may be attributed to mechanical
factors thereby confounding clinical response to
treatment [13].
Consensus Treatment Plans developed by The Child-
hood Arthritis and Rheumatology Research Alliance
(CARRA) for the treatment of CNO in patients refrac-
tory to NSAIDs and/or with active spinal lesions include
methotrexate or sulfasalazine, TNF blockers (with or
with- out methotrexate) or bisphosphonates. Use of
these Consensus Treatment Plans will provide more in-
formation on efficacy in the absence of randomised con-
trol trials [3].
Pamidronate was generally well tolerated in our cohort
but patients and parents are warned to expect infusion
effects and given anti-pyretics as required.
The main limitation of our study is that it is retro-
spective. Patient related outcomes and functional mea-
sures were not recorded at every visit. Our results
indicate essentially radiological response to treatment.
We also acknowledge that there could have been
inter-observer variability in reporting of scans. Few
patients received NSAIDs, methotrexate or steroids
before pamidronate that could have contributed to the
disease outcome.
Conclusion
From our study we conclude that bisphosphonates seem
to be effective and safe in the treatment of CNO especially
in the presence of vertebral lesions. WB-MRI is a useful
tool in assessing response to treatment. Anti-TNF agents
may be used when desired response to bisphosphonates is
not achieved. However, further prospective studies are
warranted to compare the efficacy of bisphosphonates and
anti-TNF agents in the treatment of CNO.
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Table 4 Distribution of lesions
Location Pre
pamidronate
Post
pamidronate
Number
resolved (%)
Distal tibial
metaphyses
22 7 15 (68.2)
Distal femur
metaphyses
17 2 15 (88.2)
Clavicle 16 1 15 (93.7)
Proximal tibial
metaphyses
15 5 10 (66.7)
Pelvis 11 3 8 (72.7)
Vertebra 17 3 14 (82.3)
Proximal femur
metaphyses
8 0 8 (100)
Humerus 5 2 3 (60)
Talus 6 0 6 (100)
Calcaneus 5 0 5 (100)
Ulna 5 0 5 (100)
Scapula 5 0 5 (100)
Radius 4 0 4 (100)
Ribs 4 2 2 (50)
Navicular 4 0 4(100)
Mandible 2 0 2(100)
Fibula 1 0 1(100)
Metacarpals 1 0 1(100)
Metatarsals 1 0 1(100)
Sternum 1 0 1(100)
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